Clinical trials: Multiple Sclerosis, completed
Multiple Sclerosis
Optimizing IFN Beta - 1B Dose
BetaferonR is effective in reducing relapse rate and MRI T2-weighted lesion frequency in MS patients at the dose of 8 MIU on alternate days (THE IFNB MS Study Group, 1993).
- Trial name
- Optims (NCT00473213)
- Testing
- Interferon Beta 1
- Volunteers
- 217 people
- Sponsor
- University of Turin, Italy
Multiple Sclerosis
Factors That Influence Compliance With Disease-Modifying Therapy in Multiple Sclerosis
The purpose of this study is to evaluate the coorelation between patient factors, health care provider factors, drug factors and compliance in patients with relapsing forms of multiple sclerosis (RMS) treated with Disease…
- Trial name
- NCT00223457
- Testing
- Factors that influence compliance
- Where
- United States
- Volunteers
- 1,040 people
- Sponsor
- University of Texas Southwestern Medical Center
Multiple Sclerosis
Natural Antioxidants in the Treatment of Multiple Sclerosis
The purpose of this study is to compare the effectiveness of three antioxidant regimens in treating the symptoms of multiple sclerosis (MS).
- Trial name
- NCT00010842
- Testing
- Ginkgo biloba, Alpha-lipoic acid, Vitamin E/Selenium
- Where
- United States
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Multiple Sclerosis
Yoga: Effect on Attention in Aging & Multiple Sclerosis
Changes in visual attention are common among elders and people with multiple sclerosis. The visual attention changes contribute to difficulty with day to day functioning including falls, driving and even finding one's keys on the…
- Trial name
- NCT00010998
- Testing
- Yoga
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Relapsing-Remitting Multiple Sclerosis
Omega-3 Fatty Acid Treatment in Multiple Sclerosis
Based on previous clinical studies indicating beneficial treatment effects of omega-3 fatty acids in multiple sclerosis, and the increasing evidence of anti-inflammatory effects of omega-3 fatty acids, this study aims to evaluate…
- Trial name
- NCT00360906
- Testing
- Triomar™ (omega-3 fatty acids)
- Where
- Norway
- Volunteers
- 100 people
- Sponsor
- Haukeland University Hospital
Multiple Sclerosis
Short-Term Effects of Medicinal Cannabis Therapy on Spasticity in Multiple Sclerosis
The purpose of this study is to determine whether or not smoked marijuana improves spasticity in patients with multiple sclerosis.
- Trial name
- NCT00248378
- Testing
- Smoked Cannabis
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Center for Medicinal Cannabis Research
Multiple Sclerosis, Relapsing-Remitting
Treatment of Multiple Sclerosis Using Over the Counter Inosine
The purpose of this study is to determine whether raising low levels of the natural antioxidant uric acid by the administration of a precursor, inosine, has any therapeutic effect on the progression of Relapsing Remitting…
- Trial name
- NCT00067327
- Testing
- Inosine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Multiple Sclerosis
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Copolymer 1 for Relapsing-Remitting Multiple Sclerosis
OBJECTIVES: I. Compare tolerance to and therapeutic impact of copolymer 1, a mixture of synthetic polypeptides, with placebo in patients with relapsing-remitting multiple sclerosis.
- Trial name
- NCT00004814
- Testing
- copolymer 1
- Volunteers
- 250 people
- Sponsor
- National Center for Research Resources (NCRR)
Multiple Sclerosis
A Maintenance Extension of Phase I Pilot Study of Chimeric Anti-CD4 Antibody M-T412 in Patients With Multiple Sclerosis
OBJECTIVES: I. Evaluate the safety and immunogenicity of single and multiple doses of M-T412, a chimeric murine-human anti-CD4 monoclonal antibody, in patients with multiple sclerosis. II. Evaluate the pharmacokinetics of M-T412.
- Trial name
- NCT00004816
- Testing
- monoclonal antibody M-T412
- Volunteers
- 25 people
- Sponsor
- National Center for Research Resources (NCRR)
Multiple Sclerosis
Phase I Pilot Study of Total-Body Irradiation, Anti-Thymocyte Globulin and Cyclophosphamide Followed By Syngeneic or Autologous Peripheral Blood Stem Cell Transplantation in Patients With Multiple Sclerosis
OBJECTIVES: I. Determine the toxicity of total-body irradiation, anti-thymocyte globulin, and cyclophosphamide followed by syngeneic or autologous peripheral blood stem cell (PBSC) transplantation in patients with multiple…
- Trial name
- NCT00014755
- Testing
- anti-thymocyte globulin, cyclophosphamide, filgrastim
- Where
- 6 sites in United States
- Volunteers
- 35 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Sclerosis
Phase I Study of High-Dose Cyclophosphamide and Total Body Irradiation With T Lymphocyte-Depleted Autologous Peripheral Blood Stem Cell or Bone Marrow Rescue in Patients With Multiple Sclerosis
OBJECTIVES: I. Determine the efficacy, in terms of disease progression, of high-dose cyclophosphamide and total body irradiation with T lymphocyte-depleted autologous peripheral blood stem cell or bone marrow rescue in patients…
- Trial name
- NCT00017628
- Testing
- cyclophosphamide, filgrastim, methylprednisolone
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Northwestern Memorial Hospital
Multiple Sclerosis
Antibiotic Treatment Trial Directed Against Chlamydia Pneumonia in Multiple Sclerosis
Multiple sclerosis (MS) is an inflammatory, demyelinating disease which affects the central nervous system (CNS). The etiology of MS is unknown, although the immune system appears to play a role.
- Trial name
- NCT00043264
- Testing
- Rifampin, Azithromycin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Center for Research Resources (NCRR)